Showing results (491-500 of 501) with videos related to

Sort By:
Pageof 51
Critical Care (London, England)|February 5, 2025
Time to positivity as a predictor of catheter-related bacteremia and mortality in adults with Pseudomonas aeruginosa bloodstream infectionDaniel N Marco, Maria Brey, Sergi Anguera, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 26, 2017
Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016Santiago Moreno, Antonio Antela, Felipe García, et al.
Vaccine|September 13, 2011
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)Felipe García, Juan Carlos López Bernaldo de Quirós, Carmen E Gómez, et al.
Emerging Microbes & Infections|August 1, 2024
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA ConsortiumLaura Marcos-Villar, Beatriz Perdiguero, María López-Bravo, et al.
Pilot and Feasibility Studies|June 7, 2026
Combining self-regulation and poverty reduction to prevent depression and anxiety among adolescents experiencing multi-dimensional poverty in Colombia, Nepal and South Africa: study protocol of a pilot 4-arm cluster randomised controlled trialMark J D Jordans, Crick Lund, Emily C Garman, et al.
Epidemiology and Psychiatric Sciences|December 13, 2023
Strengthening self-regulation and reducing poverty to prevent adolescent depression and anxiety: Rationale, approach and methods of the ALIVE interdisciplinary research collaboration in Colombia, Nepal and South AfricaCrick Lund, Mark J D Jordans, Emily Garman, et al.
The Journal of Antimicrobial Chemotherapy|March 1, 2015
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1Beatriz Mothe, Nuria Climent, Montserrat Plana, et al.
Infection|May 13, 2022
Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patientsVerónica Rico-Caballero, Mariana Fernández, Juan C Hurtado, et al.
Medicine|February 13, 2016
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled TrialWarren Dinges, Pierre-Marie Girard, Daniel Podzamczer, et al.
Scientific Reports|March 29, 2022
C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19Ana M Camon, Rodrigo Alonso, Francisco J Muñoz, et al.
Pageof 51